X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-03-17 | RXRX | Recursion Pharmaceuticals, Inc. | Taylor Ben R | CFO | S - Sale | $3.39 | -7,956 | 1,180,318 | -1% | -$26,971 | ||||||
| DM | 2026-03-16 | PHGE | Biomx Inc. | Yeganeh Reuven | Dir, 10% | S - Sale+OE | $5.00 | -980,000 | 0 | -100% | -$4,900,000 | |||||
2026-03-16 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $68.79 | -12,500 | 116,332 | -10% | -$859,819 | ||||||
| D | 2026-03-16 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale+OE | $9.15 | -150,000 | 400,703 | -27% | -$1,372,500 | |||||
2026-03-16 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $2.47 | -4,835 | 198,205 | -2% | -$11,942 | ||||||
2026-03-16 | ALLO | Allogene Therapeutics, Inc. | Chang David D | Pres, CEO | S - Sale | $2.47 | -47,763 | 8,063,795 | -1% | -$117,975 | ||||||
| D | 2026-03-16 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $15.16 | -21,000 | 3,837,160 | -1% | -$318,360 | |||||
2026-03-16 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $144.23 | -3,000 | 131,779 | -2% | -$432,690 | ||||||
2026-03-16 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $144.23 | -3,000 | 179,191 | -2% | -$432,690 | ||||||
| D | 2026-03-16 | CRSP | Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | S - Sale+OE | $48.26 | -3,150 | 13,143 | -19% | -$152,019 | |||||
| D | 2026-03-16 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $48.26 | -9,869 | 13,023 | -43% | -$476,278 | |||||
| D | 2026-03-16 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $48.26 | -3,450 | 91,240 | -4% | -$166,497 | |||||
| D | 2026-03-16 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $48.26 | -10,349 | 245,834 | -4% | -$499,443 | |||||
| M | 2026-03-10 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $6.83 | -972 | 76,940 | -1% | -$6,635 | |||||
| D | 2026-03-16 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $63.50 | -1,964 | 0 | -100% | -$124,714 | |||||
| M | 2026-03-12 | SRZN | Surrozen, Inc./De | Tcg Crossover Gp Ii, LLC | 10% | P - Purchase | $24.91 | +48,997 | 675,610 | +8% | +$1,220,362 | |||||
2026-03-12 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.55 | -7,043 | 507,261 | -1% | -$17,953 | ||||||
2026-03-12 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.55 | -10,076 | 608,200 | -2% | -$25,684 | ||||||
| DM | 2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $13.21 | -179,703 | 507,934 | -26% | -$2,374,058 | |||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale | $13.91 | -15,394 | 15,625 | -50% | -$214,131 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale | $14.08 | -30,593 | 293,874 | -9% | -$430,749 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $13.17 | -41,338 | 427,775 | -9% | -$544,421 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale | $13.17 | -63,103 | 272,751 | -19% | -$831,067 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $13.17 | -18,672 | 259,840 | -7% | -$245,910 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $13.17 | -470,266 | 1,522,058 | -24% | -$6,193,403 | ||||||
2026-03-11 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $13.17 | -470,167 | 2,301,113 | -17% | -$6,192,099 | ||||||
2026-03-11 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $74.78 | -20,000 | 1,152,987 | -2% | -$1,495,605 | ||||||
| M | 2026-03-12 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.79 | +13,066 | 2,524,012 | +1% | +$75,703 | |||||
| DM | 2026-03-12 | PHGE | Biomx Inc. | Yeganeh Reuven | Dir, 10% | S - Sale+OE | $5.00 | -670,000 | 0 | -100% | -$3,350,000 | |||||
2026-03-10 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $2.65 | -1,000 | 106,465 | -1% | -$2,650 | ||||||
2026-03-10 | RGNX | Regenxbio Inc. | Pakola Steve | Chief Medical Officer | S - Sale | $10.35 | -5,124 | 247,926 | -2% | -$53,033 | ||||||
| D | 2026-03-11 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $52.80 | -2,800 | 87,815 | -3% | -$147,840 | |||||
| D | 2026-03-11 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $52.80 | -9,798 | 235,558 | -4% | -$517,334 | |||||
| D | 2026-03-10 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $50.45 | -30,000 | 0 | -100% | -$1,513,560 | |||||
2026-03-12 | LCTX | Lineage Cell Therapeutics, Inc. | Culley Brian M | Pres, CEO | P - Purchase | $1.63 | +15,000 | 255,516 | +6% | +$24,375 | ||||||
| D | 2026-03-11 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $83.30 | -25,758 | 68,052 | -27% | -$2,145,673 | |||||
| M | 2026-03-09 | INKT | Mink Therapeutics, Inc. | Ryan Barbara | Dir | S - Sale | $14.70 | -1,500 | 20,406 | -7% | -$22,052 | |||||
2026-03-09 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | CEO, Pres | S - Sale | $3.35 | -28,298 | 2,262,085 | -1% | -$94,660 | ||||||
| D | 2026-03-11 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $58.59 | -2,500 | 30,867 | -7% | -$146,482 | |||||
2026-03-10 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $58.88 | -7,395 | 166,818 | -4% | -$435,440 | ||||||
2026-03-09 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $10.06 | -17,717 | 231,584 | -7% | -$178,233 | ||||||
2026-03-09 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.54 | -479 | 618,276 | 0% | -$1,215 | ||||||
2026-03-09 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.54 | -247 | 514,304 | 0% | -$626 | ||||||
2026-03-09 | ENTX | Entera Bio Ltd. | Germano Geno J | Dir | P - Purchase | $1.30 | +20,000 | 40,000 | +100% | +$26,000 | ||||||
| D | 2026-03-06 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale+OE | $3.26 | -2,090 | 173,999 | -1% | -$6,813 | |||||
| D | 2026-03-09 | ADMA | Adma Biologics, Inc. | Kestenberg-Messina Kaitlin M. | COO, SVP, Compliance | S - Sale+OE | $15.63 | -10,096 | 466,600 | -2% | -$157,800 | |||||
| DM | 2026-03-06 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.90 | -81,342 | 643,471 | -11% | -$1,211,737 | |||||
| DM | 2026-03-09 | HALO | Halozyme Therapeutics, Inc. | Caudill Cortney | SVP, COO | S - Sale+OE | $67.75 | -28,857 | 7,055 | -80% | -$1,955,160 | |||||
| M | 2026-03-06 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.82 | +4,079 | 2,510,946 | 0% | +$23,760 | |||||
2026-03-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $46.43 | -246 | 54,799 | 0% | -$11,421 | ||||||
2026-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $46.43 | -425 | 138,257 | 0% | -$19,731 | ||||||
2026-03-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $46.43 | -935 | 124,401 | -1% | -$43,408 | ||||||
| D | 2026-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $46.43 | -2,423 | 860,629 | 0% | -$112,490 | |||||
2026-03-05 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale | $15.09 | -38,074 | 324,467 | -11% | -$574,537 | ||||||
2026-03-06 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Chief Medical Officer | S - Sale | $30.00 | -10,000 | 69,747 | -13% | -$300,000 | ||||||
| D | 2026-03-06 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale+OE | $30.17 | -6,262 | 55,285 | -10% | -$188,935 | |||||
2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | CFO | S - Sale | $1.60 | -1,581 | 187,375 | -1% | -$2,530 | ||||||
2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | See Remarks | S - Sale | $1.60 | -482 | 114,549 | 0% | -$771 | ||||||
2026-03-05 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | CEO | S - Sale | $1.60 | -1,607 | 919,197 | 0% | -$2,571 | ||||||
| D | 2026-03-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $15.68 | -8,000 | 170,844 | -4% | -$125,440 | |||||
| M | 2026-03-05 | ADMA | Adma Biologics, Inc. | Elms Steve | Dir | P - Purchase | $15.53 | +14,000 | 2,143,750 | +1% | +$217,420 | |||||
2026-03-05 | ENTX | Entera Bio Ltd. | Ellis Sean | Dir | P - Purchase | $1.23 | +10,000 | 188,098 | +6% | +$12,300 | ||||||
| D | 2026-03-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $71.06 | -5,500 | 209,773 | -3% | -$390,825 | |||||
2026-03-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $263.21 | -25,000 | 1,543,155 | -2% | -$6,580,270 | ||||||
2026-03-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $263.17 | -25,000 | 1,615,253 | -2% | -$6,579,164 | ||||||
| M | 2026-03-04 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.80 | +66,818 | 2,506,867 | +3% | +$387,622 | |||||
| D | 2026-03-03 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale+OE | $15.30 | -48,044 | 15,394 | -76% | -$735,073 | |||||
| DM | 2026-03-03 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $16.09 | -92,823 | 575,235 | -14% | -$1,493,428 | |||||
| D | 2026-03-04 | LONA | Leonabio, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $5.37 | -5,156 | 59,894 | -8% | -$27,688 | |||||
| D | 2026-03-04 | LONA | Leonabio, Inc. | Renninger Robert | CFO | S - Sale+OE | $5.37 | -906 | 15,851 | -5% | -$4,865 | |||||
| D | 2026-03-04 | LONA | Leonabio, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $5.37 | -1,328 | 18,376 | -7% | -$7,131 | |||||
| D | 2026-03-04 | LONA | Leonabio, Inc. | Church Kevin | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $5.37 | -1,359 | 25,178 | -5% | -$7,298 | |||||
| D | 2026-03-04 | LONA | Leonabio, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $5.37 | -1,720 | 15,887 | -10% | -$9,236 | |||||
| DM | 2026-03-03 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale+OE | $23.53 | -3,299 | 58,832 | -5% | -$77,627 | |||||
2026-03-04 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $17.96 | -139 | 22,554 | -1% | -$2,496 | ||||||
| A | 2026-02-11 | TECX | Tectonic Therapeutic, Inc. | Reicin Alise | CEO | P - Purchase | $21.10 | +2,500 | 362,077 | +1% | +$52,750 | |||||
2026-03-04 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $76.67 | -8,366 | 71,292 | -11% | -$641,421 | ||||||
2026-03-02 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $70.22 | -2,000 | 181,371 | -1% | -$140,431 | ||||||
| M | 2026-03-02 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $16.19 | -24,233 | 1,155,291 | -2% | -$392,329 | |||||
| DM | 2026-03-02 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $69.52 | -50,000 | 767,780 | -6% | -$3,476,157 | |||||
| DM | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $86.54 | -5,958 | 73,810 | -7% | -$515,594 | |||||
| DM | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $87.24 | -10,508 | 117,134 | -8% | -$916,669 | |||||
| DM | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $87.50 | -12,471 | 232,588 | -5% | -$1,091,231 | |||||
2026-03-02 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $2.60 | -7,132 | 203,040 | -3% | -$18,543 | ||||||
2026-03-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.02 | -5,394 | 263,693 | -2% | -$10,894 | ||||||
2026-03-02 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $17.92 | -5,466 | 613,471 | -1% | -$97,974 | ||||||
2026-03-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.02 | -474 | 15,434 | -3% | -$957 | ||||||
2026-03-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.02 | -749 | 68,028 | -1% | -$1,513 | ||||||
| M | 2026-02-27 | INKT | Mink Therapeutics, Inc. | Ryan Barbara | Dir | S - Sale | $10.85 | -500 | 21,906 | -2% | -$5,426 | |||||
2026-03-03 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.46 | -170,000 | 6,259,863 | -3% | -$588,200 | ||||||
2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $90.13 | -81,866 | 675,341 | -11% | -$7,378,583 | ||||||
2026-03-02 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $5.08 | -2,104 | 31,750 | -6% | -$10,691 | ||||||
2026-03-02 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $5.09 | -2,996 | 61,978 | -5% | -$15,237 | ||||||
| D | 2026-03-02 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $35.18 | -21,421 | 1,262 | -94% | -$753,530 | |||||
| M | 2026-03-02 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.76 | +71,411 | 2,440,049 | +3% | +$411,624 | |||||
2026-03-02 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale | $35.30 | -10,305 | 16,080 | -39% | -$363,767 | ||||||
| D | 2026-02-27 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale+OE | $3.01 | -9,406 | 173,999 | -5% | -$28,311 | |||||
| D | 2026-03-02 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $101.23 | -36,000 | 948,053 | -4% | -$3,644,354 | |||||
| M | 2026-02-27 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $15.85 | -524,998 | 1,934,247 | -21% | -$8,320,613 | |||||
| D | 2026-03-02 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | Chief Accounting Officer | S - Sale+OE | $267.60 | -750 | 22,366 | -3% | -$200,700 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |